title: Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
abstract: An open-label prospective cross-over trial was performed to compare the efficacy and adverse effects of nateglinide with those of voglibose on Japanese early type 2 diabetes (who were oral hypoglycemic agent naïve and whose HbA(1C) levels were between 7.0 and 7.9% before treatment). Fourteen patients received 270 mg/day of nateglinide and 15 patients received 0.6 mg/day of voglibose. After 12 weeks of either therapy, the drugs were switched and treatment was continued for another 12 weeks. After 3-month treatment with each drug, HbA(1C) value decreased significantly (baseline HbA(1C) 7.24 +/- 0.42%, 6.70 +/- 0.47% with nateglinide: p<0.01, 6.93 +/- 0.62% with voglibose: p<0.05) but the difference in the effect between nateglinide and voglibose was not significant (p = 0.121). Symptoms related to hypoglycemia (e.g., increased appetite, palpitation, sweating, tremor) were scarcely observed with either voglibose or nateglinide treatments. Abdominal fullness/borborygmi was frequently reported, with variable severity, by patients on voglibose but this was absent or mild in those on nateglinide. After completion of both arms of the study, more patients favored nateglinide than voglibose. Our results suggest that nateglinide is an effective and safe drug in the treatment of early type 2 diabetes, similar to voglibose.
authors.affiliation: Department of Internal Medicine, Nishinomiya Municipal Central Hospital, Japan.
authors.forename: Shogo
authors.initials: S
authors.lastname: Kurebayashi
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kawasumi
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Kawamori
authors.forename: Takahisa
authors.initials: T
authors.lastname: Hirose
mesh_terms: D000368:Aged; D001066:Appetite / Q000187:drug effects; D001835:Body Weight; D018592:Cross-Over Studies; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005500:Follow-Up Studies; D041981:Gastrointestinal Tract / Q000187:drug effects; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007294:Inositol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D000520:alpha-Glucosidases / Q000627:therapeutic use
chemical_list: D003510:Cyclohexanes; D006442:Glycated Hemoglobin; D007294:Inositol; D008055:Lipids; D000077715:Nateglinide; D010649:Phenylalanine; D000520:alpha-Glucosidases; C102817:voglibose